57
US tariff proposals targeting branded pharmaceuticals risk draining money from research and development and slowing future medical breakthroughs, Bayer’s Chief Operating Officer Sebastian Guth said in an exclusive interview with Arabian Business.
“Every dollar we spend on tariffs is $1 we can’t spend on research and development,” Guth said, calling the move a long-term trade-off that could blunt innovation far beyond any short-term financial effects.
“The impact may be felt in 10 or 15 or 20 years,” he added, noting the lengthy timelines and high failure rates in drug development.
